McKesson Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- McKesson Corporation (NYSE: MCK) operates as a diversified healthcare services company, primarily engaged in pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty solutions, and prescription technology services. The company distributes pharmaceuticals and medical supplies through its North American Pharmaceutical segment, which serves retail and community pharmacies, specialty care settings, and health systems across the United States and Canada via a network of distribution centers; its Oncology and Multispecialty segment provides practice management, technology solutions, specialty drug distribution, clinical trial services, group purchasing, and pharmacy solutions for community-based oncology practices and providers in retina and ophthalmology; its Medical-Surgical Solutions segment merchandises and distributes more than 285,000 national brand products alongside McKesson's own brands of medical-surgical supplies, pharmaceuticals, laboratory equipment, and supplies to physician offices, surgery centers, long-term care providers, home health agencies, health systems, government facilities, and online retailers in the United States; and its Prescription Technology Solutions segment offers medication access, affordability, and adherence programs, including prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support connecting patients, pharmacies, providers, payers, and biopharma companies. [fetch:https://www.mckesson.com/about-us/business-segments/] Founded in 1833 and headquartered in Irving, Texas, McKesson serves healthcare providers, pharmacies, biopharma manufacturers, governments, and consumers primarily in North America, with additional distribution and retail operations in Norway, which it agreed to sell in August 2025. [fetch:https://www.mckesson.com/about-us/history/] In recent strategic developments, McKesson acquired a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures), associated with Florida Cancer Specialists & Research Institute, for $2.49 billion in August 2024 to bolster oncology care; welcomed Florida Cancer Specialists as a member of The US Oncology Network; acquired a controlling interest in PRISM Vision Group to expand into ophthalmology and retina care; formed a joint venture between US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute to advance oncology research and clinical trials; and announced in September 2025 a corporate restructuring into four segments—North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective fiscal 2026, alongside plans to separate the Medical-Surgical Solutions segment and updated long-term growth targets including 13% to 16% adjusted earnings per share growth. [fetch:https://www.mckesson.com/about-us/history/]
McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
McKesson Q4 Earnings Call Highlights
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
Compared to Estimates, McKesson (MCK) Q4 Earnings: A Look at Key Metrics
McKesson (MCK) Surpasses Q4 Earnings Estimates
McKesson expects 2027 profit slightly above estimates on drug distribution strength
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
Should You Buy, Sell, or Hold McKesson Before Q4 Earnings?
Countdown to McKesson (MCK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
Concurrent Investment Advisors LLC Raises Holdings in McKesson Corporation $MCK
William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?
Should Xtrackers Russell US Multifactor ETF (DEUS) Be on Your Investing Radar?
Why Congress Can't Stop Loading Up on These 3 Stocks in 2026